利妥昔单抗在儿童原发性肾病综合征的应用新进展
New Progress in the Application of Rituximab in Children with Primary Nephrotic Syndrome
DOI: 10.12677/ACM.2021.117465, PDF,   
作者: 李 建, 颜嘉葳：右江民族医学院研究生院，广西 百色；刘运广*：右江民族医学院附属医院，广西 百色
关键词: 肾病综合征；儿童；利妥昔单抗；治疗；Nephrotic Syndrome； Children； Rituximab； Treatment
摘要: 原发性肾病综合征(Primary nephrotic syndrome, PNS)是儿童最常见的肾小球疾病，其发病与自身免疫有关，约25%的患者表现为频复发或激素依赖、激素耐药，进而发展成难治性肾病综合征，以单独的糖皮质激素或联合免疫抑制剂治疗为主。利妥昔单抗(rituximab，RTX)是一种诱导B细胞溶解和凋亡的嵌合抗CD20单克隆抗体，能够预防或延缓儿童原发性肾病综合征患者的复发，延缓进入终末期肾病。近年来，已有多个病例回顾性研究和随机对照试验证实利妥昔单抗在治疗原发性肾病综合的有效性和安全性，极大的改善了儿童原发性肾病综合征的预后。本文就RTX的作用机制、在儿童PNS临床应用疗效及不良反应进行综述。
Abstract: Primary nephrotic syndrome (PNS) is the most common glomerular disease in children. Its onset is related to autoimmunity. Approximately 25% of patients show frequent relapses or hormone dependence and hormone resistance, and then develop into refractory nephrotic syndrome which is mainly treated with glucocorticoid alone or combined with immunosuppressive agents. Rituximab (RTX) is a chimeric anti-CD20 monoclonal antibody that induces B cell lysis and apoptosis. It can prevent or delay the recurrence of children with primary nephrotic syndrome and delay the entry into end-stage renal disease. In recent years, retrospective studies and randomized controlled trials of multiple cases have confirmed the effectiveness and safety of rituximab in the treatment of primary nephrotic syndrome, which has greatly improved the prognosis of children with primary nephrotic syndrome. This article reviews the mechanism of action of RTX, its clinical efficacy and adverse reactions in Children PNS.
文章引用：李建, 颜嘉葳, 刘运广. 利妥昔单抗在儿童原发性肾病综合征的应用新进展[J]. 临床医学进展, 2021, 11(7): 3203-3208. https://doi.org/10.12677/ACM.2021.117465

参考文献

[1] Bertelli, R., Bonanni, A., Di, D.A., et al. (2016) Regulatory T Cells and Minimal Change Nephropathy: In the Midst of a Complex Network. Clinical & Experimental Immunology, 183, 166-174. [Google Scholar] [CrossRef] [PubMed]
[2] Noone, D., Iijima, K. and Parekh, R. (2018) Idiopathic Nephrotic Syndrome in Children. The Lancet (London, England), 392, 61-74. [Google Scholar] [CrossRef] 
[3] Kamei, K., et al. (2020) Rituximab Therapy for Refractory Steroid-Resistant Nephrotic Syndrome in Children. Pediatric Nephrology, 35, 17-24. [Google Scholar] [CrossRef] [PubMed]
[4] Iijima, K., Sako, M., Kamei, K. and Nozu, K. (2018) Rituximab in Steroid-Sensitive Nephrotic Syndrome: Lessons from Clinical Trials. Pediatric Nephrology, 33, 1449-1455. [Google Scholar] [CrossRef] [PubMed]
[5] Iijima, K., Sako, M. and Nozu, K. (2017) Rituximab for Nephrotic Syndrome in Children. Clinical and Experimental Nephrology, 21, 193-202. [Google Scholar] [CrossRef] [PubMed]
[6] Liu, K. and Mohan, C. (2009) Altered B-Cell Signaling in Lupus. Autoimmunity Reviews, 8, 214-218. [Google Scholar] [CrossRef] [PubMed]
[7] Chan, O.T., Hannum, L.G., Haberman, A.M., Madaio, M.P. and Shlomchik, M.J. (1999) A Novel Mouse with B Cells But Lacking Serum Antibody Reveals an Antibody-Independent Role for B Cells in Murine Lupus. Journal of Experimental Medicine, 189, 1639-1648. [Google Scholar] [CrossRef] [PubMed]
[8] Sfi kakis, P.P., Boletis, J.N., Lionaki, S., et al. (2005) Remission of Proliferative Lupus Nephritis Following B Cell Depletion Therapy Is Preceded by Down-Regulation of the T Cell Costimulatory Molecule CD40 Ligand: An Open-Label Trial. Arthritis & Rheumatology, 52, 501-513. [Google Scholar] [CrossRef] [PubMed]
[9] Bugatti, S., Codullo, V., Caporali, R. and Montecucco, C. (2007) B Cells in Rheumatoid Arthritis. Autoimmunity Reviews, 7, 137-142. [Google Scholar] [CrossRef] [PubMed]
[10] Maloney, D.G. (2001) Mechanism of Action of Rituximab. Anticancer Drugs, 12, S1-S4.
[11] Stasi, R., Cooper, N., Del Poeta, G., et al. (2008) Analysis of Regulatory T-Cell Changes in Patients with Idiopathic Thrombocytopenic Purpura Receiving B Cell-Depleting Therapy with Rituximab. Blood, 112, 1147-1150. [Google Scholar] [CrossRef] [PubMed]
[12] Fornoni, A., Sageshima, J., Wei, C., Merscher-Gomez, S., Aguillon-Prada, R., Jauregui, A.N., et al. (2011) Rituximab Targets Podocytes in Recurrent Focal Segmental Glomerulosclerosis. Science Translational Medicine, 3, 85ra46. [Google Scholar] [CrossRef] [PubMed]
[13] Takahashi, Y., Ikezumi, Y. and Saitoh, A. (2017) Rituximab Protects Podocytes and Exerts Anti-528 Proteinuric Effects in Rat Adriamycin-Induced Nephropathy Independent of B-Lymphocytes. Nephrology (Carlton), 22, 49-57. [Google Scholar] [CrossRef] [PubMed]
[14] Iijima, K., et al. (2014) Rituximab for Childhood-Onset, Complicated, Frequently Relapsing Nephrotic Syndrome or Steroid-Dependent Nephrotic Syndrome: A Multicentre, Double-Blind, Randomised, Placebo-Controlled Trial. The Lancet, 384, 1273-1281. [Google Scholar] [CrossRef] 
[15] Ruggenenti, P., et al. (2014) Rituximab in Steroid-Dependent or Frequently Relapsing Idiopathic Nephrotic Syndrome. Journal of the American Society of Nephrology, 25, 850-863. [Google Scholar] [CrossRef] 
[16] Van Horebeek, I., et al. (2017) Rituximab in Children with Steroid-Dependent Nephrotic Syndrome: Experience of a Tertiary Center and Review of the Literature. Acta Clinica Belgica, 72, 147-155. [Google Scholar] [CrossRef] [PubMed]
[17] Basu, B., et al. (2018) Efficacy of Rituximab vs Tacrolimus in Pediatric Corticosteroid-Dependent Nephrotic Syndrome. JAMA Pediatrics, 172, 757. [Google Scholar] [CrossRef] [PubMed]
[18] Bagga, A., Moudgil, A. and Sinha, A. (2007) Rituximab in Patients with the Steroid-Resistant Nephrotic Syndrome. The New England Journal of Medicine, 356, 2751-2752. [Google Scholar] [CrossRef] 
[19] Sinha, A., et al. (2015) Efficacy and Safety of Rituximab in Children with Difficult-to-Treat Nephrotic Syndrome. Nephrology Dialysis Transplantation, 30, 96-106. [Google Scholar] [CrossRef] [PubMed]
[20] Kamei, K., et al. (2014) Rituximab Treatment Combined with Methylprednisolone Pulse Therapy and Immunosuppressants for Childhood Steroid-Resistant Nephrotic Syndrome. Pediatric Nephrology, 29, 1181-1187. [Google Scholar] [CrossRef] [PubMed]
[21] Hoseini, R., et al. (2018) Efficacy and Safety of Rituximab in Children with Steroid- and Cyclosporine-Resistant and Steroid- and Cyclosporine-Dependent Nephrotic Syndrome. Iranian Journal of Kidney Diseases, 12, 27-32.
[22] Suyama, K., et al. (2016) Rituximab and Low-Dose Cyclosporine Combination Therapy for Steroid-Resistant Focal Segmental Glomerulosclerosis. Pediatrics International, 58, 219-223. [Google Scholar] [CrossRef] [PubMed]
[23] Prytuła, A., et al. (2010) Rituximab in Refractory Nephrotic Syndrome. Pediatric Nephrology, 25, 461-468. [Google Scholar] [CrossRef] [PubMed]
[24] Sun, L., et al. (2014) Efficacy of Rituximab Therapy in Children with Refractory Nephrotic Syndrome: A Prospective Observational Study in Shanghai. World Journal of Pediatrics, 10, 59-63. [Google Scholar] [CrossRef] [PubMed]
[25] Bonanni, A., et al. (2018) Adverse Events Linked with the Use of Chimeric and Humanized Anti-CD20 Antibodies in Children with Idiopathic Nephrotic Syndrome. British Journal of Clinical Pharmacology, 84, 1238-1249. [Google Scholar] [CrossRef] [PubMed]
[26] Parmentier, C., et al. (2020) Immunoglobulin Serum Levels in Rituximab-Treated Patients with Steroid-Dependent Nephrotic Syndrome. Pediatric Nephrology, 35, 455-462. [Google Scholar] [CrossRef] [PubMed]
[27] Fujinaga, S., et al. (2019) Long-Term Outcomes after Early Treatment with Rituximab for Japanese Children with Cyclosporine- and Steroid-Resistant Nephrotic Syndrome. Pediatric Nephrology, 34, 353-357. [Google Scholar] [CrossRef] [PubMed]
[28] Sato, M., et al. (2013) Atypical Pneumocystis jiroveci Pneumonia with Multiple Nodular Granulomas after Rituximab for Refractory Nephrotic Syndrome. Pediatric Nephrology, 28, 145-149. [Google Scholar] [CrossRef] [PubMed]
[29] Ardelean, D.S., et al. (2010) Severe Ulcerative Colitis after Rituximab Therapy. Pediatrics (Evanston), 126, e243. [Google Scholar] [CrossRef] [PubMed]
[30] Chaumais, M., et al. (2009) Fatal Pulmonary Fibrosis after Rituximab Administration. Pediatric Nephrology, 24, 1753-1755. [Google Scholar] [CrossRef] [PubMed]
[31] Grenda, R., Jarmużek, W., Rubik, J., Migdał, M. and Pronicki, M. (2015) Fatal Rituximab-Associated Lung Injury Syndrome in a Patient Treated with Rituximab for Recurrence of Post-Transplant Nephrotic Syndrome. Pediatric Transplantation, 19, E115-E120. [Google Scholar] [CrossRef] [PubMed]

为你推荐